Vertex Pharmaceuticals (VRTX) Total Debt (2009 - 2016)

Vertex Pharmaceuticals' Total Debt history runs 6 years deep, the most recent figure standing at $75.0 million for Q4 2016.

• On a quarterly basis, Total Debt fell 66.5% year-over-year to $75.0 million in Q4 2016; TTM through Dec 2016 was $75.0 million, a 66.5% decrease from a year earlier, with the FY2016 full-year figure at $75.0 million, down 66.5% from the prior year.
• Total Debt eased to $75.0 million in Q4 2016 per VRTX's latest filing, from $297.8 million in the prior quarter.
• Across five years, Total Debt topped out at $297.8 million in Q3 2016 and bottomed at $75.0 million in Q4 2016.
• The 3-year median for Total Debt is $294.8 million (2015), against an average of $266.3 million.
• Biggest YoY gain for Total Debt was 0.99% in 2016; the steepest drop was 66.5% in 2016.
• Year by year, Total Debt stood at $294.8 million in 2014, then declined by 24.06% to $223.9 million in 2015, then tumbled by 66.5% to $75.0 million in 2016.
• Per Business Quant, the three latest VRTX Total Debt figures stand at $75.0 million (Q4 2016), $297.8 million (Q3 2016), and $296.5 million (Q2 2016).